nodes	percent_of_prediction	percent_of_DWPC	metapath
Alitretinoin—CYP1A2—Carmustine—lymphatic system cancer	0.113	0.536	CbGbCtD
Alitretinoin—ABCB1—Mitoxantrone—lymphatic system cancer	0.0465	0.22	CbGbCtD
Alitretinoin—ABCB1—Vincristine—lymphatic system cancer	0.032	0.152	CbGbCtD
Alitretinoin—ABCB1—Methotrexate—lymphatic system cancer	0.0194	0.0918	CbGbCtD
Alitretinoin—Confusional state—Bleomycin—lymphatic system cancer	0.000659	0.000835	CcSEcCtD
Alitretinoin—Vision blurred—Carmustine—lymphatic system cancer	0.000659	0.000835	CcSEcCtD
Alitretinoin—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000657	0.000832	CcSEcCtD
Alitretinoin—Tremor—Carmustine—lymphatic system cancer	0.000655	0.00083	CcSEcCtD
Alitretinoin—Oedema—Bleomycin—lymphatic system cancer	0.000653	0.000828	CcSEcCtD
Alitretinoin—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000653	0.000828	CcSEcCtD
Alitretinoin—Erythema—Mitoxantrone—lymphatic system cancer	0.00065	0.000824	CcSEcCtD
Alitretinoin—Infection—Bleomycin—lymphatic system cancer	0.000649	0.000823	CcSEcCtD
Alitretinoin—Anaemia—Carmustine—lymphatic system cancer	0.000646	0.000819	CcSEcCtD
Alitretinoin—Back pain—Vincristine—lymphatic system cancer	0.000645	0.000818	CcSEcCtD
Alitretinoin—Vomiting—Teniposide—lymphatic system cancer	0.000645	0.000817	CcSEcCtD
Alitretinoin—Sepsis—Methotrexate—lymphatic system cancer	0.000643	0.000815	CcSEcCtD
Alitretinoin—Agitation—Carmustine—lymphatic system cancer	0.000642	0.000814	CcSEcCtD
Alitretinoin—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00064	0.000811	CcSEcCtD
Alitretinoin—Asthenia—Fludarabine—lymphatic system cancer	0.000639	0.00081	CcSEcCtD
Alitretinoin—Rash—Teniposide—lymphatic system cancer	0.000639	0.00081	CcSEcCtD
Alitretinoin—Dermatitis—Teniposide—lymphatic system cancer	0.000639	0.00081	CcSEcCtD
Alitretinoin—Headache—Teniposide—lymphatic system cancer	0.000635	0.000805	CcSEcCtD
Alitretinoin—Pruritus—Fludarabine—lymphatic system cancer	0.00063	0.000799	CcSEcCtD
Alitretinoin—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00063	0.000799	CcSEcCtD
Alitretinoin—Back pain—Mitoxantrone—lymphatic system cancer	0.000628	0.000797	CcSEcCtD
Alitretinoin—Anorexia—Bleomycin—lymphatic system cancer	0.000623	0.000789	CcSEcCtD
Alitretinoin—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000618	0.000783	CcSEcCtD
Alitretinoin—Anaemia—Vincristine—lymphatic system cancer	0.000617	0.000782	CcSEcCtD
Alitretinoin—Agitation—Vincristine—lymphatic system cancer	0.000613	0.000777	CcSEcCtD
Alitretinoin—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000612	0.000776	CcSEcCtD
Alitretinoin—Photosensitivity—Methotrexate—lymphatic system cancer	0.000612	0.000776	CcSEcCtD
Alitretinoin—Hypotension—Bleomycin—lymphatic system cancer	0.000611	0.000774	CcSEcCtD
Alitretinoin—Diarrhoea—Fludarabine—lymphatic system cancer	0.00061	0.000773	CcSEcCtD
Alitretinoin—Convulsion—Carmustine—lymphatic system cancer	0.000605	0.000768	CcSEcCtD
Alitretinoin—Hypertension—Carmustine—lymphatic system cancer	0.000603	0.000765	CcSEcCtD
Alitretinoin—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000603	0.000764	CcSEcCtD
Alitretinoin—Nausea—Teniposide—lymphatic system cancer	0.000602	0.000763	CcSEcCtD
Alitretinoin—Anaemia—Mitoxantrone—lymphatic system cancer	0.0006	0.000761	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000595	0.000755	CcSEcCtD
Alitretinoin—Chest pain—Carmustine—lymphatic system cancer	0.000595	0.000754	CcSEcCtD
Alitretinoin—Myalgia—Carmustine—lymphatic system cancer	0.000595	0.000754	CcSEcCtD
Alitretinoin—Anxiety—Carmustine—lymphatic system cancer	0.000593	0.000752	CcSEcCtD
Alitretinoin—Paraesthesia—Bleomycin—lymphatic system cancer	0.000587	0.000744	CcSEcCtD
Alitretinoin—Malaise—Mitoxantrone—lymphatic system cancer	0.000586	0.000743	CcSEcCtD
Alitretinoin—Dyspnoea—Bleomycin—lymphatic system cancer	0.000583	0.000738	CcSEcCtD
Alitretinoin—Renal failure acute—Methotrexate—lymphatic system cancer	0.000582	0.000738	CcSEcCtD
Alitretinoin—Convulsion—Vincristine—lymphatic system cancer	0.000578	0.000733	CcSEcCtD
Alitretinoin—Hypertension—Vincristine—lymphatic system cancer	0.000576	0.00073	CcSEcCtD
Alitretinoin—Confusional state—Carmustine—lymphatic system cancer	0.000575	0.000729	CcSEcCtD
Alitretinoin—Oedema—Carmustine—lymphatic system cancer	0.00057	0.000723	CcSEcCtD
Alitretinoin—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00057	0.000722	CcSEcCtD
Alitretinoin—Decreased appetite—Bleomycin—lymphatic system cancer	0.000568	0.00072	CcSEcCtD
Alitretinoin—Myalgia—Vincristine—lymphatic system cancer	0.000568	0.00072	CcSEcCtD
Alitretinoin—Visual disturbance—Methotrexate—lymphatic system cancer	0.000567	0.000719	CcSEcCtD
Alitretinoin—Cough—Mitoxantrone—lymphatic system cancer	0.000567	0.000719	CcSEcCtD
Alitretinoin—Infection—Carmustine—lymphatic system cancer	0.000567	0.000718	CcSEcCtD
Alitretinoin—Vomiting—Fludarabine—lymphatic system cancer	0.000567	0.000718	CcSEcCtD
Alitretinoin—Convulsion—Mitoxantrone—lymphatic system cancer	0.000563	0.000714	CcSEcCtD
Alitretinoin—Rash—Fludarabine—lymphatic system cancer	0.000562	0.000712	CcSEcCtD
Alitretinoin—Dermatitis—Fludarabine—lymphatic system cancer	0.000561	0.000712	CcSEcCtD
Alitretinoin—Hypertension—Mitoxantrone—lymphatic system cancer	0.000561	0.000711	CcSEcCtD
Alitretinoin—Pain—Bleomycin—lymphatic system cancer	0.000559	0.000708	CcSEcCtD
Alitretinoin—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000558	0.000708	CcSEcCtD
Alitretinoin—Headache—Fludarabine—lymphatic system cancer	0.000558	0.000708	CcSEcCtD
Alitretinoin—Tachycardia—Carmustine—lymphatic system cancer	0.000557	0.000706	CcSEcCtD
Alitretinoin—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000553	0.000701	CcSEcCtD
Alitretinoin—Chest pain—Mitoxantrone—lymphatic system cancer	0.000553	0.000701	CcSEcCtD
Alitretinoin—Myalgia—Mitoxantrone—lymphatic system cancer	0.000553	0.000701	CcSEcCtD
Alitretinoin—Anxiety—Mitoxantrone—lymphatic system cancer	0.000551	0.000699	CcSEcCtD
Alitretinoin—Lethargy—Methotrexate—lymphatic system cancer	0.000548	0.000695	CcSEcCtD
Alitretinoin—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000548	0.000695	CcSEcCtD
Alitretinoin—Discomfort—Mitoxantrone—lymphatic system cancer	0.000546	0.000693	CcSEcCtD
Alitretinoin—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000544	0.00069	CcSEcCtD
Alitretinoin—Oedema—Vincristine—lymphatic system cancer	0.000544	0.00069	CcSEcCtD
Alitretinoin—Anorexia—Carmustine—lymphatic system cancer	0.000544	0.000689	CcSEcCtD
Alitretinoin—Infection—Vincristine—lymphatic system cancer	0.000541	0.000686	CcSEcCtD
Alitretinoin—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000538	0.000683	CcSEcCtD
Alitretinoin—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000538	0.000681	CcSEcCtD
Alitretinoin—Confusional state—Mitoxantrone—lymphatic system cancer	0.000535	0.000678	CcSEcCtD
Alitretinoin—Nervous system disorder—Vincristine—lymphatic system cancer	0.000534	0.000677	CcSEcCtD
Alitretinoin—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000533	0.000676	CcSEcCtD
Alitretinoin—Hypotension—Carmustine—lymphatic system cancer	0.000533	0.000676	CcSEcCtD
Alitretinoin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00053	0.000672	CcSEcCtD
Alitretinoin—Oedema—Mitoxantrone—lymphatic system cancer	0.00053	0.000672	CcSEcCtD
Alitretinoin—Nausea—Fludarabine—lymphatic system cancer	0.000529	0.000671	CcSEcCtD
Alitretinoin—Infection—Mitoxantrone—lymphatic system cancer	0.000527	0.000668	CcSEcCtD
Alitretinoin—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000526	0.000667	CcSEcCtD
Alitretinoin—Shock—Mitoxantrone—lymphatic system cancer	0.000522	0.000661	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00052	0.000659	CcSEcCtD
Alitretinoin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000519	0.000658	CcSEcCtD
Alitretinoin—Urticaria—Bleomycin—lymphatic system cancer	0.000519	0.000658	CcSEcCtD
Alitretinoin—Anorexia—Vincristine—lymphatic system cancer	0.000519	0.000658	CcSEcCtD
Alitretinoin—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000517	0.000656	CcSEcCtD
Alitretinoin—Body temperature increased—Bleomycin—lymphatic system cancer	0.000517	0.000655	CcSEcCtD
Alitretinoin—Insomnia—Carmustine—lymphatic system cancer	0.000516	0.000654	CcSEcCtD
Alitretinoin—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000515	0.000653	CcSEcCtD
Alitretinoin—Irritability—Methotrexate—lymphatic system cancer	0.000513	0.00065	CcSEcCtD
Alitretinoin—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000513	0.00065	CcSEcCtD
Alitretinoin—Paraesthesia—Carmustine—lymphatic system cancer	0.000512	0.000649	CcSEcCtD
Alitretinoin—Mood swings—Methotrexate—lymphatic system cancer	0.000509	0.000645	CcSEcCtD
Alitretinoin—Hypotension—Vincristine—lymphatic system cancer	0.000509	0.000645	CcSEcCtD
Alitretinoin—Dyspnoea—Carmustine—lymphatic system cancer	0.000508	0.000645	CcSEcCtD
Alitretinoin—Somnolence—Carmustine—lymphatic system cancer	0.000507	0.000643	CcSEcCtD
Alitretinoin—Anorexia—Mitoxantrone—lymphatic system cancer	0.000505	0.000641	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000496	0.000629	CcSEcCtD
Alitretinoin—Decreased appetite—Carmustine—lymphatic system cancer	0.000496	0.000628	CcSEcCtD
Alitretinoin—Hypotension—Mitoxantrone—lymphatic system cancer	0.000495	0.000628	CcSEcCtD
Alitretinoin—Insomnia—Vincristine—lymphatic system cancer	0.000492	0.000624	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000492	0.000624	CcSEcCtD
Alitretinoin—Paraesthesia—Vincristine—lymphatic system cancer	0.000489	0.00062	CcSEcCtD
Alitretinoin—Constipation—Carmustine—lymphatic system cancer	0.000488	0.000618	CcSEcCtD
Alitretinoin—Pain—Carmustine—lymphatic system cancer	0.000488	0.000618	CcSEcCtD
Alitretinoin—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000484	0.000614	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000483	0.000612	CcSEcCtD
Alitretinoin—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000481	0.00061	CcSEcCtD
Alitretinoin—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000476	0.000604	CcSEcCtD
Alitretinoin—Decreased appetite—Vincristine—lymphatic system cancer	0.000473	0.0006	CcSEcCtD
Alitretinoin—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000473	0.000599	CcSEcCtD
Alitretinoin—Somnolence—Mitoxantrone—lymphatic system cancer	0.000471	0.000598	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00047	0.000596	CcSEcCtD
Alitretinoin—Feeling abnormal—Carmustine—lymphatic system cancer	0.00047	0.000596	CcSEcCtD
Alitretinoin—Fatigue—Vincristine—lymphatic system cancer	0.000469	0.000595	CcSEcCtD
Alitretinoin—Asthenia—Bleomycin—lymphatic system cancer	0.000469	0.000594	CcSEcCtD
Alitretinoin—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000467	0.000592	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000466	0.000591	CcSEcCtD
Alitretinoin—Pain—Vincristine—lymphatic system cancer	0.000466	0.00059	CcSEcCtD
Alitretinoin—Constipation—Vincristine—lymphatic system cancer	0.000466	0.00059	CcSEcCtD
Alitretinoin—Asthma—Methotrexate—lymphatic system cancer	0.000465	0.000589	CcSEcCtD
Alitretinoin—Pruritus—Bleomycin—lymphatic system cancer	0.000462	0.000586	CcSEcCtD
Alitretinoin—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000461	0.000584	CcSEcCtD
Alitretinoin—Fatigue—Mitoxantrone—lymphatic system cancer	0.000457	0.000579	CcSEcCtD
Alitretinoin—Pancreatitis—Methotrexate—lymphatic system cancer	0.000455	0.000577	CcSEcCtD
Alitretinoin—Pain—Mitoxantrone—lymphatic system cancer	0.000453	0.000575	CcSEcCtD
Alitretinoin—Constipation—Mitoxantrone—lymphatic system cancer	0.000453	0.000575	CcSEcCtD
Alitretinoin—Abdominal pain—Carmustine—lymphatic system cancer	0.000451	0.000572	CcSEcCtD
Alitretinoin—Body temperature increased—Carmustine—lymphatic system cancer	0.000451	0.000572	CcSEcCtD
Alitretinoin—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000445	0.000565	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000445	0.000564	CcSEcCtD
Alitretinoin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000437	0.000554	CcSEcCtD
Alitretinoin—Neutropenia—Methotrexate—lymphatic system cancer	0.000434	0.000551	CcSEcCtD
Alitretinoin—Dysuria—Methotrexate—lymphatic system cancer	0.000434	0.000551	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000434	0.00055	CcSEcCtD
Alitretinoin—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000432	0.000547	CcSEcCtD
Alitretinoin—Abdominal pain—Vincristine—lymphatic system cancer	0.00043	0.000546	CcSEcCtD
Alitretinoin—Body temperature increased—Vincristine—lymphatic system cancer	0.00043	0.000546	CcSEcCtD
Alitretinoin—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000424	0.000538	CcSEcCtD
Alitretinoin—Urticaria—Mitoxantrone—lymphatic system cancer	0.000421	0.000534	CcSEcCtD
Alitretinoin—Hypersensitivity—Carmustine—lymphatic system cancer	0.00042	0.000533	CcSEcCtD
Alitretinoin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000419	0.000531	CcSEcCtD
Alitretinoin—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000419	0.000531	CcSEcCtD
Alitretinoin—Pneumonia—Methotrexate—lymphatic system cancer	0.000417	0.000528	CcSEcCtD
Alitretinoin—Vomiting—Bleomycin—lymphatic system cancer	0.000415	0.000527	CcSEcCtD
Alitretinoin—Infestation—Methotrexate—lymphatic system cancer	0.000414	0.000525	CcSEcCtD
Alitretinoin—Drowsiness—Methotrexate—lymphatic system cancer	0.000414	0.000525	CcSEcCtD
Alitretinoin—Infestation NOS—Methotrexate—lymphatic system cancer	0.000414	0.000525	CcSEcCtD
Alitretinoin—Depression—Methotrexate—lymphatic system cancer	0.000413	0.000524	CcSEcCtD
Alitretinoin—Rash—Bleomycin—lymphatic system cancer	0.000412	0.000522	CcSEcCtD
Alitretinoin—Dermatitis—Bleomycin—lymphatic system cancer	0.000412	0.000522	CcSEcCtD
Alitretinoin—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000411	0.000521	CcSEcCtD
Alitretinoin—Asthenia—Carmustine—lymphatic system cancer	0.000409	0.000519	CcSEcCtD
Alitretinoin—Renal failure—Methotrexate—lymphatic system cancer	0.000407	0.000516	CcSEcCtD
Alitretinoin—Stomatitis—Methotrexate—lymphatic system cancer	0.000404	0.000512	CcSEcCtD
Alitretinoin—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000403	0.00051	CcSEcCtD
Alitretinoin—Hypersensitivity—Vincristine—lymphatic system cancer	0.000401	0.000508	CcSEcCtD
Alitretinoin—Sweating—Methotrexate—lymphatic system cancer	0.000397	0.000503	CcSEcCtD
Alitretinoin—Haematuria—Methotrexate—lymphatic system cancer	0.000395	0.000501	CcSEcCtD
Alitretinoin—Epistaxis—Methotrexate—lymphatic system cancer	0.000391	0.000495	CcSEcCtD
Alitretinoin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000391	0.000495	CcSEcCtD
Alitretinoin—Asthenia—Vincristine—lymphatic system cancer	0.000391	0.000495	CcSEcCtD
Alitretinoin—Diarrhoea—Carmustine—lymphatic system cancer	0.00039	0.000495	CcSEcCtD
Alitretinoin—Nausea—Bleomycin—lymphatic system cancer	0.000388	0.000492	CcSEcCtD
Alitretinoin—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000387	0.00049	CcSEcCtD
Alitretinoin—Asthenia—Mitoxantrone—lymphatic system cancer	0.00038	0.000482	CcSEcCtD
Alitretinoin—Dizziness—Carmustine—lymphatic system cancer	0.000377	0.000478	CcSEcCtD
Alitretinoin—Haemoglobin—Methotrexate—lymphatic system cancer	0.000374	0.000474	CcSEcCtD
Alitretinoin—Diarrhoea—Vincristine—lymphatic system cancer	0.000373	0.000472	CcSEcCtD
Alitretinoin—Haemorrhage—Methotrexate—lymphatic system cancer	0.000372	0.000471	CcSEcCtD
Alitretinoin—Hepatitis—Methotrexate—lymphatic system cancer	0.000372	0.000471	CcSEcCtD
Alitretinoin—Pharyngitis—Methotrexate—lymphatic system cancer	0.000369	0.000468	CcSEcCtD
Alitretinoin—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000367	0.000465	CcSEcCtD
Alitretinoin—Urethral disorder—Methotrexate—lymphatic system cancer	0.000365	0.000462	CcSEcCtD
Alitretinoin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000363	0.00046	CcSEcCtD
Alitretinoin—Vomiting—Carmustine—lymphatic system cancer	0.000363	0.00046	CcSEcCtD
Alitretinoin—Dizziness—Vincristine—lymphatic system cancer	0.00036	0.000456	CcSEcCtD
Alitretinoin—Rash—Carmustine—lymphatic system cancer	0.00036	0.000456	CcSEcCtD
Alitretinoin—Dermatitis—Carmustine—lymphatic system cancer	0.000359	0.000455	CcSEcCtD
Alitretinoin—Visual impairment—Methotrexate—lymphatic system cancer	0.000358	0.000454	CcSEcCtD
Alitretinoin—Headache—Carmustine—lymphatic system cancer	0.000357	0.000453	CcSEcCtD
Alitretinoin—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000352	0.000446	CcSEcCtD
Alitretinoin—Eye disorder—Methotrexate—lymphatic system cancer	0.000347	0.00044	CcSEcCtD
Alitretinoin—Tinnitus—Methotrexate—lymphatic system cancer	0.000347	0.000439	CcSEcCtD
Alitretinoin—Vomiting—Vincristine—lymphatic system cancer	0.000346	0.000439	CcSEcCtD
Alitretinoin—Rash—Vincristine—lymphatic system cancer	0.000343	0.000435	CcSEcCtD
Alitretinoin—Dermatitis—Vincristine—lymphatic system cancer	0.000343	0.000435	CcSEcCtD
Alitretinoin—Headache—Vincristine—lymphatic system cancer	0.000341	0.000432	CcSEcCtD
Alitretinoin—Nausea—Carmustine—lymphatic system cancer	0.000339	0.000429	CcSEcCtD
Alitretinoin—Angiopathy—Methotrexate—lymphatic system cancer	0.000337	0.000428	CcSEcCtD
Alitretinoin—Vomiting—Mitoxantrone—lymphatic system cancer	0.000337	0.000427	CcSEcCtD
Alitretinoin—Rash—Mitoxantrone—lymphatic system cancer	0.000334	0.000424	CcSEcCtD
Alitretinoin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000334	0.000423	CcSEcCtD
Alitretinoin—Chills—Methotrexate—lymphatic system cancer	0.000334	0.000423	CcSEcCtD
Alitretinoin—Headache—Mitoxantrone—lymphatic system cancer	0.000332	0.000421	CcSEcCtD
Alitretinoin—Alopecia—Methotrexate—lymphatic system cancer	0.000329	0.000417	CcSEcCtD
Alitretinoin—Mental disorder—Methotrexate—lymphatic system cancer	0.000326	0.000413	CcSEcCtD
Alitretinoin—Malnutrition—Methotrexate—lymphatic system cancer	0.000324	0.00041	CcSEcCtD
Alitretinoin—Erythema—Methotrexate—lymphatic system cancer	0.000324	0.00041	CcSEcCtD
Alitretinoin—Nausea—Vincristine—lymphatic system cancer	0.000323	0.00041	CcSEcCtD
Alitretinoin—Nausea—Mitoxantrone—lymphatic system cancer	0.000315	0.000399	CcSEcCtD
Alitretinoin—Back pain—Methotrexate—lymphatic system cancer	0.000313	0.000397	CcSEcCtD
Alitretinoin—Vision blurred—Methotrexate—lymphatic system cancer	0.000305	0.000387	CcSEcCtD
Alitretinoin—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.0003	0.000381	CcSEcCtD
Alitretinoin—Anaemia—Methotrexate—lymphatic system cancer	0.000299	0.000379	CcSEcCtD
Alitretinoin—Malaise—Methotrexate—lymphatic system cancer	0.000292	0.00037	CcSEcCtD
Alitretinoin—Cough—Methotrexate—lymphatic system cancer	0.000282	0.000358	CcSEcCtD
Alitretinoin—Convulsion—Methotrexate—lymphatic system cancer	0.00028	0.000356	CcSEcCtD
Alitretinoin—Arthralgia—Methotrexate—lymphatic system cancer	0.000276	0.000349	CcSEcCtD
Alitretinoin—Chest pain—Methotrexate—lymphatic system cancer	0.000276	0.000349	CcSEcCtD
Alitretinoin—Myalgia—Methotrexate—lymphatic system cancer	0.000276	0.000349	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000274	0.000347	CcSEcCtD
Alitretinoin—Discomfort—Methotrexate—lymphatic system cancer	0.000272	0.000345	CcSEcCtD
Alitretinoin—Confusional state—Methotrexate—lymphatic system cancer	0.000266	0.000338	CcSEcCtD
Alitretinoin—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000264	0.000335	CcSEcCtD
Alitretinoin—Infection—Methotrexate—lymphatic system cancer	0.000262	0.000333	CcSEcCtD
Alitretinoin—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000259	0.000328	CcSEcCtD
Alitretinoin—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000259	0.000328	CcSEcCtD
Alitretinoin—Skin disorder—Methotrexate—lymphatic system cancer	0.000257	0.000325	CcSEcCtD
Alitretinoin—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000255	0.000324	CcSEcCtD
Alitretinoin—Anorexia—Methotrexate—lymphatic system cancer	0.000252	0.000319	CcSEcCtD
Alitretinoin—Hypotension—Methotrexate—lymphatic system cancer	0.000247	0.000313	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000241	0.000305	CcSEcCtD
Alitretinoin—Insomnia—Methotrexate—lymphatic system cancer	0.000239	0.000303	CcSEcCtD
Alitretinoin—Paraesthesia—Methotrexate—lymphatic system cancer	0.000237	0.000301	CcSEcCtD
Alitretinoin—Dyspnoea—Methotrexate—lymphatic system cancer	0.000236	0.000299	CcSEcCtD
Alitretinoin—Somnolence—Methotrexate—lymphatic system cancer	0.000235	0.000298	CcSEcCtD
Alitretinoin—Dyspepsia—Methotrexate—lymphatic system cancer	0.000233	0.000295	CcSEcCtD
Alitretinoin—Decreased appetite—Methotrexate—lymphatic system cancer	0.00023	0.000291	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000228	0.000289	CcSEcCtD
Alitretinoin—Fatigue—Methotrexate—lymphatic system cancer	0.000228	0.000289	CcSEcCtD
Alitretinoin—Pain—Methotrexate—lymphatic system cancer	0.000226	0.000286	CcSEcCtD
Alitretinoin—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000218	0.000276	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000216	0.000274	CcSEcCtD
Alitretinoin—Urticaria—Methotrexate—lymphatic system cancer	0.00021	0.000266	CcSEcCtD
Alitretinoin—Abdominal pain—Methotrexate—lymphatic system cancer	0.000209	0.000265	CcSEcCtD
Alitretinoin—Body temperature increased—Methotrexate—lymphatic system cancer	0.000209	0.000265	CcSEcCtD
Alitretinoin—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000195	0.000247	CcSEcCtD
Alitretinoin—Asthenia—Methotrexate—lymphatic system cancer	0.00019	0.00024	CcSEcCtD
Alitretinoin—Pruritus—Methotrexate—lymphatic system cancer	0.000187	0.000237	CcSEcCtD
Alitretinoin—Diarrhoea—Methotrexate—lymphatic system cancer	0.000181	0.000229	CcSEcCtD
Alitretinoin—Dizziness—Methotrexate—lymphatic system cancer	0.000175	0.000221	CcSEcCtD
Alitretinoin—Vomiting—Methotrexate—lymphatic system cancer	0.000168	0.000213	CcSEcCtD
Alitretinoin—Rash—Methotrexate—lymphatic system cancer	0.000167	0.000211	CcSEcCtD
Alitretinoin—Dermatitis—Methotrexate—lymphatic system cancer	0.000166	0.000211	CcSEcCtD
Alitretinoin—Headache—Methotrexate—lymphatic system cancer	0.000165	0.00021	CcSEcCtD
Alitretinoin—Nausea—Methotrexate—lymphatic system cancer	0.000157	0.000199	CcSEcCtD
